| First Author | Lu JF | Year | 2022 |
| Journal | PLoS Biol | Volume | 20 |
| Issue | 2 | Pages | e3001517 |
| PubMed ID | 35202387 | Mgi Jnum | J:342573 |
| Mgi Id | MGI:6885030 | Doi | 10.1371/journal.pbio.3001517 |
| Citation | Lu JF, et al. (2022) Camptothecin effectively treats obesity in mice through GDF15 induction. PLoS Biol 20(2):e3001517 |
| abstractText | Elevated circulating levels of growth differentiation factor 15 (GDF15) have been shown to reduce food intake and lower body weight through activation of hindbrain receptor glial-derived neurotrophic factor (GDNF) receptor alpha-like (GFRAL) in rodents and nonhuman primates, thus endogenous induction of this peptide holds promise for obesity treatment. Here, through in silico drug-screening methods, we found that small molecule Camptothecin (CPT), a previously identified drug with potential antitumor activity, is a GDF15 inducer. Oral CPT administration increases circulating GDF15 levels in diet-induced obese (DIO) mice and genetic ob/ob mice, with elevated Gdf15 expression predominantly in the liver through activation of integrated stress response. In line with GDF15's anorectic effect, CPT suppresses food intake, thereby reducing body weight, blood glucose, and hepatic fat content in obese mice. Conversely, CPT loses these beneficial effects when Gdf15 is inhibited by a neutralizing antibody or AAV8-mediated liver-specific knockdown. Similarly, CPT failed to reduce food intake and body weight in GDF15's specific receptor GFRAL-deficient mice despite high levels of GDF15. Together, these results indicate that CPT is a promising anti-obesity agent through activation of GDF15-GFRAL pathway. |
